Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis

The British Journal of Dermatology
D VidalAgustín Alomar

Abstract

Imiquimod is a modifier of the immune response that has been proven to be an effective treatment for basal cell carcinoma (BCC). However, its mechanism of action is still unknown. To determine whether imiquimod modifies the expression of proteins such as Bcl-2, Ki67, p53 and the BCC apoptotic index. Thirty caucasian patients with primary BCCs larger than 8 mm in diameter were included in a double-blind randomized clinical and immunohistochemical study which was designed in a reference university hospital. The 30 BCCs were randomized in two treatment arms between September 2001 and February 2002. Twenty-four BCCs were treated with imiquimod 5% cream and six BCCs with Aldara (3M Pharmaceuticals) excipient. Histological samples were obtained before treatment and on days 8 and 15 during the course of treatment. The BCC expression of Bcl-2, Ki67 and p53 was determined in paraffin samples and the apoptotic index of the BCC was studied using the TUNEL technique (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick end labelling) in frozen samples. All variables were evaluated quantitatively in fields with a magnification x 400. The BCCs treated with imiquimod showed a decrease in the expression of Bcl-2...Continue Reading

References

Nov 1, 1992·The Journal of Cell Biology·Y GavrieliS A Ben-Sasson
Mar 29, 1995·International Journal of Cancer. Journal International Du Cancer·J Rodríguez-Villanueva, T J McDonnell
Mar 1, 1995·Journal of Clinical Pathology·E E MooneyE C Sweeney
May 1, 1995·The British Journal of Dermatology·M E VerhaeghH A Neumann
Nov 1, 1995·The British Journal of Dermatology·E HealyJ L Rees
Jul 1, 1996·Journal of Clinical Pathology·M H al-SaderM Leader
Jun 1, 1997·Journal of the American Academy of Dermatology·C A Raskin
May 12, 1998·Surgical Oncology·R J BoldD J McConkey
Jun 25, 1998·Histopathology·J J Rippey
Nov 26, 1999·Journal of the American Academy of Dermatology·K R BeutnerM L Owens
Apr 25, 2000·Journal of Cutaneous Pathology·R A AbdelsayedO P Sangueza
Jul 8, 2000·Journal of Cutaneous Pathology·P K RamdialR Chetty
Apr 20, 2001·Journal of the American Academy of Dermatology·R MarksUNKNOWN Australasian Multicentre Trial Group
Aug 21, 2001·The Journal of Investigative Dermatology·M RaisovaC C Geilen
Apr 30, 2002·The American Journal of Dermatopathology·Bozena Baima, Michael Sticherling
Jul 9, 2002·The British Journal of Dermatology·Y ScrivenerB Cribier
Aug 2, 2002·Journal of Cutaneous Pathology·Claudia M L TilliH A Martino Neumann
Aug 28, 2002·Journal of the American Academy of Dermatology·John K GeisseMary Owens
Aug 7, 2003·Journal of the National Cancer Institute·Margarete SchönMichael P Schön
Oct 22, 2003·Archives of Dermatology·Mirjana UrosevicReinhard Dummer
Nov 18, 2003·The British Journal of Dermatology·R DummerG Burg

❮ Previous
Next ❯

Citations

Dec 25, 2009·Archives of Dermatological Research·Chul-Ho KimHee Young Kang
Feb 20, 2009·Current Treatment Options in Oncology·M J Patel, N J Liégeois
Jan 8, 2008·Oncogene·M P Schön, M Schön
Jun 1, 2013·Indian Journal of Dermatology·Effat KhodaeianiHossein Alikhah
Sep 4, 2012·Lasers in Medical Science·Juliana S de C MonteiroJean Nunes dos Santos
Dec 5, 2012·Expert Opinion on Investigational Drugs·Thomas MeyerEggert Stockfleth
Mar 6, 2009·International Journal of Dermatology·Vincenzo De GiorgiDaniela Massi
Apr 25, 2006·Experimental Dermatology·Meinhard SchillerMatthias Gunzer
Dec 11, 2007·The British Journal of Dermatology·M VatveG Gupta
Dec 11, 2007·The British Journal of Dermatology·M P Schön, M Schön
Jun 22, 2011·Dermatologic Therapy·Makiko Asakura, Hiroyuki Miura
Nov 9, 2010·Journal of the European Academy of Dermatology and Venereology : JEADV·K M AlGhamdi, A Kumar
Aug 24, 2010·Journal of Cutaneous Pathology·Keira L BarrMaxwell A Fung
Jun 16, 2010·The Australasian Journal of Dermatology·Neil MacphersonGeoff Watt
Jun 17, 2009·Biochemical and Biophysical Research Communications·Jae Youn YiEunkyung Chung
Jan 31, 2006·Expert Opinion on Therapeutic Targets·Michael P Schön, Margarete Schön
Nov 4, 2016·Annals of Diagnostic Pathology·Salam N Jawad, Bashar H Abdullah
Mar 7, 2013·Nature Communications·Anne WalterMaries van den Broek
Apr 9, 2009·Expert Opinion on Pharmacotherapy·Gérald E PiérardPascale Quatresooz
Feb 23, 2019·Immunotherapy·Irene RussoMauro Alaibac
Nov 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Holbrook Kohrt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis